Literature DB >> 21746931

Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth.

Bo Zhao1, James Zou, Hongfang Wang, Eric Johannsen, Chih-wen Peng, John Quackenbush, Jessica C Mar, Cynthia Casson Morton, Matthew L Freedman, Stephen C Blacklow, Jon C Aster, Bradley E Bernstein, Elliott Kieff.   

Abstract

Epstein-Barr virus nuclear antigen 2 (EBNA2) regulation of transcription through the cell transcription factor RBPJ is essential for resting B-lymphocyte (RBL) conversion to immortal lymphoblast cell lines (LCLs). ChIP-seq of EBNA2 and RBPJ sites in LCL DNA found EBNA2 at 5,151 and RBPJ at 10,529 sites. EBNA2 sites were enriched for RBPJ (78%), early B-cell factor (EBF, 39%), RUNX (43%), ETS (39%), NFκB (22%), and PU.1 (22%) motifs. These motif associations were confirmed by LCL RBPJ ChIP-seq finding 72% RBPJ occupancy and Encyclopedia Of DNA Elements LCL ChIP-seq finding EBF, NFκB RELA, and PU.1 at 54%, 31%, and 17% of EBNA2 sites. EBNA2 and RBPJ were predominantly at intergene and intron sites and only 14% at promoter sites. K-means clustering of EBNA2 site transcription factors identified RELA-ETS, EBF-RUNX, EBF, ETS, RBPJ, and repressive RUNX clusters, which ranked from highest to lowest in H3K4me1 signals and nucleosome depletion, indicative of active chromatin. Surprisingly, although quantitatively less, the same genome sites in RBLs exhibited similar high-level H3K4me1 signals and nucleosome depletion. The EBV genome also had an LMP1 promoter EBF site, which proved critical for EBNA2 activation. LCL HiC data mapped intergenic EBNA2 sites to EBNA2 up-regulated genes. FISH and chromatin conformation capture linked EBNA2/RBPJ enhancers 428 kb 5' of MYC to MYC. These data indicate that EBNA2 evolved to target RBL H3K4me1 modified, nucleosome-depleted, nonpromoter sites to drive B-lymphocyte proliferation in primary human infection. The primed RBL program likely supports antigen-induced proliferation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21746931      PMCID: PMC3169132          DOI: 10.1073/pnas.1108892108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

1.  8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC.

Authors:  Nasim Ahmadiyeh; Mark M Pomerantz; Chiara Grisanzio; Paula Herman; Li Jia; Vanessa Almendro; Housheng Hansen He; Myles Brown; X Shirley Liu; Matt Davis; Jennifer L Caswell; Christine A Beckwith; Adam Hills; Laura Macconaill; Gerhard A Coetzee; Meredith M Regan; Matthew L Freedman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-07       Impact factor: 11.205

2.  Histone modifications at human enhancers reflect global cell-type-specific gene expression.

Authors:  Nathaniel D Heintzman; Gary C Hon; R David Hawkins; Pouya Kheradpour; Alexander Stark; Lindsey F Harp; Zhen Ye; Leonard K Lee; Rhona K Stuart; Christina W Ching; Keith A Ching; Jessica E Antosiewicz-Bourget; Hui Liu; Xinmin Zhang; Roland D Green; Victor V Lobanenkov; Ron Stewart; James A Thomson; Gregory E Crawford; Manolis Kellis; Bing Ren
Journal:  Nature       Date:  2009-03-18       Impact factor: 49.962

3.  The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer.

Authors:  Mark M Pomerantz; Nasim Ahmadiyeh; Li Jia; Paula Herman; Michael P Verzi; Harshavardhan Doddapaneni; Christine A Beckwith; Jennifer A Chan; Adam Hills; Matt Davis; Keluo Yao; Sarah M Kehoe; Heinz-Josef Lenz; Christopher A Haiman; Chunli Yan; Brian E Henderson; Baruch Frenkel; Jordi Barretina; Adam Bass; Josep Tabernero; José Baselga; Meredith M Regan; J Robert Manak; Ramesh Shivdasani; Gerhard A Coetzee; Matthew L Freedman
Journal:  Nat Genet       Date:  2009-06-28       Impact factor: 38.330

4.  Nucleosome dynamics define transcriptional enhancers.

Authors:  Housheng Hansen He; Clifford A Meyer; Hyunjin Shin; Shannon T Bailey; Gang Wei; Qianben Wang; Yong Zhang; Kexin Xu; Min Ni; Mathieu Lupien; Piotr Mieczkowski; Jason D Lieb; Keji Zhao; Myles Brown; X Shirley Liu
Journal:  Nat Genet       Date:  2010-03-07       Impact factor: 38.330

5.  Downregulation of RUNX1 by RUNX3 requires the RUNX3 VWRPY sequence and is essential for Epstein-Barr virus-driven B-cell proliferation.

Authors:  Gareth Brady; Hannah J Whiteman; Lindsay C Spender; Paul J Farrell
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

6.  c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells.

Authors:  Nathalie Faumont; Stéphanie Durand-Panteix; Martin Schlee; Sebastian Grömminger; Marino Schuhmacher; Michael Hölzel; Gerhard Laux; Reinhard Mailhammer; Andreas Rosenwald; Louis M Staudt; Georg W Bornkamm; Jean Feuillard
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

7.  Transcription factor EBF restricts alternative lineage options and promotes B cell fate commitment independently of Pax5.

Authors:  Jagan M R Pongubala; Daniel L Northrup; David W Lancki; Kay L Medina; Thomas Treiber; Eric Bertolino; Matthew Thomas; Rudolf Grosschedl; David Allman; Harinder Singh
Journal:  Nat Immunol       Date:  2008-01-06       Impact factor: 25.606

8.  Comprehensive mapping of long-range interactions reveals folding principles of the human genome.

Authors:  Erez Lieberman-Aiden; Nynke L van Berkum; Louise Williams; Maxim Imakaev; Tobias Ragoczy; Agnes Telling; Ido Amit; Bryan R Lajoie; Peter J Sabo; Michael O Dorschner; Richard Sandstrom; Bradley Bernstein; M A Bender; Mark Groudine; Andreas Gnirke; John Stamatoyannopoulos; Leonid A Mirny; Eric S Lander; Job Dekker
Journal:  Science       Date:  2009-10-09       Impact factor: 47.728

9.  A Myc-regulated transcriptional network controls B-cell fate in response to BCR triggering.

Authors:  Jernej Murn; Irena Mlinaric-Rascan; Pierre Vaigot; Olivier Alibert; Vincent Frouin; Xavier Gidrol
Journal:  BMC Genomics       Date:  2009-07-17       Impact factor: 3.969

10.  Genome-wide analysis of transcription factor binding sites based on ChIP-Seq data.

Authors:  Anton Valouev; David S Johnson; Andreas Sundquist; Catherine Medina; Elizabeth Anton; Serafim Batzoglou; Richard M Myers; Arend Sidow
Journal:  Nat Methods       Date:  2008-09       Impact factor: 28.547

View more
  110 in total

1.  Linking hematopoietic regeneration to developmental signaling pathways: a story of BMP and Wnt.

Authors:  Teresa V Bowman; Eirini Trompouki; Leonard I Zon
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

Review 2.  The double-edged sword of Notch signaling in cancer.

Authors:  Andrew P South; Raymond J Cho; Jon C Aster
Journal:  Semin Cell Dev Biol       Date:  2012-01-30       Impact factor: 7.727

Review 3.  The RUNX complex: reaching beyond haematopoiesis into immunity.

Authors:  Dominic Chih-Cheng Voon; Yit Teng Hor; Yoshiaki Ito
Journal:  Immunology       Date:  2015-10-25       Impact factor: 7.397

4.  Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.

Authors:  Italo Tempera; Alessandra De Leo; Andrew V Kossenkov; Matteo Cesaroni; Hui Song; Noor Dawany; Louise Showe; Fang Lu; Priyankara Wikramasinghe; Paul M Lieberman
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

5.  The NF-κB genomic landscape in lymphoblastoid B cells.

Authors:  Bo Zhao; Luis A Barrera; Ina Ersing; Bradford Willox; Stefanie C S Schmidt; Hannah Greenfeld; Hufeng Zhou; Sarah B Mollo; Tommy T Shi; Kaoru Takasaki; Sizun Jiang; Ellen Cahir-McFarland; Manolis Kellis; Martha L Bulyk; Elliott Kieff; Benjamin E Gewurz
Journal:  Cell Rep       Date:  2014-08-21       Impact factor: 9.423

6.  The Epstein-Barr virus microRNA BART11-5p targets the early B-cell transcription factor EBF1.

Authors:  Nathan Ross; Maher K Gandhi; Jamie P Nourse
Journal:  Am J Blood Res       Date:  2013-08-19

7.  A single amino acid in EBNA-2 determines superior B lymphoblastoid cell line growth maintenance by Epstein-Barr virus type 1 EBNA-2.

Authors:  Stelios Tzellos; Paulo B Correia; Claudio Elgueta Karstegl; Laila Cancian; Julian Cano-Flanagan; Michael J McClellan; Michelle J West; Paul J Farrell
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

8.  Statin-induced changes in gene expression in EBV-transformed and native B-cells.

Authors:  Eugene Bolotin; Angela Armendariz; Kyungpil Kim; Seok-Jin Heo; Dario Boffelli; Kelan Tantisira; Jerome I Rotter; Ronald M Krauss; Marisa W Medina
Journal:  Hum Mol Genet       Date:  2013-10-30       Impact factor: 6.150

9.  Epigenomic elements enriched in the promoters of autoimmunity susceptibility genes.

Authors:  Mikhail G Dozmorov; Jonathan D Wren; Marta E Alarcón-Riquelme
Journal:  Epigenetics       Date:  2013-11-08       Impact factor: 4.528

Review 10.  Notch inhibitors for cancer treatment.

Authors:  Ingrid Espinoza; Lucio Miele
Journal:  Pharmacol Ther       Date:  2013-02-28       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.